Table 4. Multivariate analyses of the risk factors for DFS in HCC patients.
|
Training cohort |
Validation cohort |
|||||
|---|---|---|---|---|---|---|
| P-value | HR | 95.0% CI | P-value | HR | 95.0% CI | |
| FGF-2 |
0.199 |
1.670 |
0.764–3.650 |
0.162 |
1.665 |
0.814–3.402 |
| IFN-α2 |
<0.001 |
7.486 |
2.820–19.871 |
0.008 |
2.561 |
1.283–5.114 |
| GRO |
0.016 |
2.426 |
1.176–5.006 |
0.292 |
1.452 |
0.726–2.907 |
| IL-8 |
0.834 |
0.928 |
0.462–1.864 |
0.015 |
2.505 |
1.198–5.240 |
| IP-10 |
0.063 |
1.878 |
0.967–3.644 |
0.096 |
1.698 |
0.911–3.166 |
| VEGF |
0.354 |
1.397 |
0.689–2.835 |
0.171 |
1.637 |
0.808–3.315 |
| Tumour diameter |
0.073 |
1.947 |
0.939–4.038 |
0.002 |
4.554 |
1.759–11.787 |
| Tumour multiplicity |
0.019 |
2.117 |
1.129–3.972 |
0.102 |
2.100 |
0.863–5.113 |
| TNM stage | 0.348 | 1.406 | 0.690–2.862 | 0.604 | 0.765 | 0.287–2.104 |
Abbreviations: CI=confidence interval; DFS=disease-free survival; FGF-2=fibroblast growth factor 2; GRO=growth-regulated oncogene; HR=hazard ratio; IFN-α2=interferon alpha-2; IL-8=interleukin 8; IP-10=interferon gamma-induced protein 10; TNM=tumour node metastasis; VEGF=vascular endothelial growth factor.